Fate Therapeutics Inc
Closed
SectorHealthcare
2.73 -3.53
Overview
Share price change
24h
Min
2.5300000000000002
Max
2.83
Income | 1.2M -31M |
|---|---|
Sales | -70K 1.3M |
EPS | -0.26 |
Profit margin | -2,402.848 |
Employees | 161 |
EBITDA | 12M -30M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +68.31% upside |
Next Earnings | 10 sie 2026 |
|---|
Market Cap | 8.8M 262M |
|---|---|
Previous open | 6.26 |
Previous close | 2.73 |
Fate Therapeutics Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Fate Therapeutics Inc Forecast
Price Target
By TipRanks
68.31% upside
12 Months Forecast
Average 4.78 USD 68.31%
High 7 USD
Low 2.2 USD
Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
